Westlake Corporation (WLK): what the price assumes

boothcheck covers Westlake Corporation (WLK) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/WLK

Headline

FieldValue
TickerWLK
CompanyWestlake Corporation
Current price$78.72/sh
CompositionHousing Products 31% / Infrastructure Products 6% / Performance Materials 36% / Essential Materials 27%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)4.5%
Operating margin (mid-cycle)16.3%
Margin compression (value-band)-11.8pp
Trailing margin (depressed year)-15.7%
Multiple paid7x mid-cycle operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7.9% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-0.38σ
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power value, while growth-DCF lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.24x2expensive
Earnings0.79x1justifies
Relative—0—
Growth5.73x3expensive

Families that justify the price: Asset, Earnings Families that call it expensive: Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.8%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$13.755.73xyesReference only (OCF-based, capex excluded): OCF $0.4B
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative——noP/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus
Simple DDMGrowth$6.0513.01xyesDPS $2.13, g=-19.2% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$-26.25—noStage 1: -200% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$66.781.18xyesReference only (book value floor): BV/sh $66.78, ROE negative
Two-Stage Excess ReturnAsset$60.101.31xyesReference only (book value with convergence): BV/sh $66.78, ROE converges to ke
Discounted Future Market CapGrowth$37.602.09xyesRev $11.0B, growth -9% (input: historical growth; tapered), Terminal P/S: 0.8x / 0.9x / 1.1x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$99.600.79xyesNormalized EBIT (5y avg op income, one-time charges added back) $1.26B × (1−21%) / WACC 5.8% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——noRevenue $10.98B × sector P/S 1.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Economic-Unit Decomposition (Sum Of The Parts)

Material operating units span distinct economics, so a single sector multiple or target margin is not representative. Consolidated cash-flow lenses may remain as secondary checks, while segment SOTP is primary.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Housing and Infrastructure Productsoperatingenterprise$4.1b—$8.8b indicative EV subtotalindicative enterprise value
Performance and Essential Materialsoperatingenterprise$7.0b—$6.7b indicative EV subtotalindicative enterprise value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$3.1b
Net debt / NOPAT (after-tax)2.21x
Net debt / operating income (pre-tax)1.74x
Interest coverage9.5x
Share count CAGR (buyback)-0.2%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 16.3%); the trailing year was depressed.

Bullet Takeaways

Bull Case

The counterintuitive fact about Westlake is that the company just posted a quarterly loss and the valuation engine reads it as supported, not stretched. Trailing operating margin is deeply negative, near minus 16 percent, and Q1 2026 produced a net loss of 169 million dollars, yet the earnings-power and relative-multiple frames both land at or above today's 80-dollar price while the growth-DCF, which would normally lift a cyclical, is the one calling it expensive. That inversion of the usual pattern is the tell: the market is not pricing Westlake on the trough quarter; it is pricing it on what a normalized chemical and building-products company earns across a full cycle. The number that anchors it is the normalized earnings-power read of about 98 dollars, built on a five-year-average operating income of 1.26 billion dollars rather than the depressed trailing figure.

The balance sheet is what lets a cyclical wait for the cycle to turn. Westlake holds roughly 2.5 billion dollars of cash, book value per share is about 66.78 dollars, and the dividend has been maintained through the downturn. A chemicals company at the bottom of the cycle with a multi-billion-dollar cash cushion is not at risk; it is positioned to fund cost reductions, hold its dividend, and emerge with operating leverage when prices recover. Management is leaning into that, reaffirming a 600-million-dollar EBITDA uplift target for 2026 and executing a restructuring program targeting roughly 175 million dollars of annual cost savings.

The demand drivers are cyclical, not broken. Westlake's Housing and Infrastructure Products segment is tied to construction, and the company itself notes that sales rise in the second and third calendar quarters on inventory restocking and improved construction weather (FY2025 10-K, accession 0001262823-26-000016). The same filing flags that mortgage rates weigh on housing demand in the near term (FY2025 10-K, accession 0001262823-26-000016), which is exactly the headwind that reverses when rates ease. With essential and performance materials providing the commodity-chemical base and housing products providing the building-cycle leverage, Westlake is a normalized-earnings bet trading near its through-cycle value with a balance sheet built to survive the wait. JPMorgan's May upgrade and the company's free-cash-flow recovery path into 2027 reflect that the trough may be closer to its end than its middle.

Bear Case

Read Westlake through the chemical cycle and the picture is sobering, because this is a business at a low that may not be as low as it looks. The first quarter of 2026 was ugly: net sales of 2.7 billion dollars missed estimates, gross profit fell 52 percent to 112 million dollars, and EBITDA dropped from 288 million dollars a year earlier to 150 million dollars, with weakness across PVC, polyethylene, caustic soda, chlorine, and building products. The danger in a cyclical is mistaking peak earnings for sustainable earnings, but the symmetric danger is mistaking a structural downshift for a cyclical trough. Global commodity-chemical capacity has expanded, particularly low-cost supply, and when an industry adds capacity into soft demand, the recovery is shallower and longer than the bulls expect. The reaffirmed 600-million-dollar EBITDA uplift target depends on both volumes and pricing cooperating, and Q1 showed neither.

The demand side is hostage to housing, and housing is hostage to rates. Westlake's own filing is explicit that the level of mortgage interest rates impacting consumer affordability is expected to unfavorably affect demand for housing construction in the near term, and therefore the products its Housing and Infrastructure segment makes (FY2025 10-K, accession 0001262823-26-000016). The segment's income already fell to 56 million dollars on lower pipe-and-fittings prices and reduced roofing volumes, and management guided the segment to the lower end of prior ranges, citing cost inflation and a slow start to construction season. If rates stay elevated, the building-products leg that was supposed to diversify Westlake away from pure commodity chemicals weakens alongside the chemicals.

The valuation offers an asset floor but not much momentum. The price already sits near the normalized earnings-power value, which means the easy re-rating from distressed to fair has happened, and the analyst tape reflects it: JPMorgan moved only to Neutral at a 90-dollar target, BofA downgraded to Neutral, and S&P cut the corporate rating into BB territory, a reminder that the credit market sees more cyclical and balance-sheet risk than the equity narrative admits. Customer and distributor behavior adds noise: the filing notes sales depend on individual decisions of distributors and dealers on inventory levels and their views on demand (FY2025 10-K, accession 0001262823-26-000016), so a destocking wave can deepen the trough beyond what end-demand alone would suggest. If the cost program underdelivers or the cycle stays soft, there is asset value beneath the price but little to drive it higher.

Valuation

Westlake is a cyclical caught at a loss-making trough, so its valuation must be read on normalized rather than trailing earnings, and the X-ray does exactly that. The earnings-power frame is the anchor: capitalizing a normalized EBIT of about 1.26 billion dollars (the five-year average operating income, with one-time charges added back) at the cost of capital produces a value near 98 dollars, above the current 80-dollar price. The asset frame is the floor: book value per share is about 66.78 dollars, putting the excess-return references in the 60-to-67-dollar range. So the price sits between its asset floor and its normalized earnings power, which is the textbook location for a quality cyclical at the bottom of its cycle. The growth-DCF and future-market-cap reads land lower because they extrapolate the recent revenue decline, which is the trough being projected forward, and should be discounted accordingly.

Because trailing operating income is negative, the price cannot be inverted into a clean implied-growth figure; the solve falls below the floor, which is the engine's way of saying the current earnings do not anchor the valuation. The honest read is that buying Westlake here is buying a normalized-earnings stream at a modest discount, with the timing of normalization unknown. The reliability of the normalized number is reasonable given a long operating history, but it assumes the next cycle resembles the last, and added global chemical capacity is a reason it might not.

The practical synthesis is that Westlake is a value-and-asset name, not a growth bet, exactly as the engine characterizes it. The 2.5-billion-dollar cash position and the maintained dividend mean an investor is paid to wait, and the asset floor limits downside in an orderly recovery. The upside is the gap between today's price and the roughly 98-dollar normalized earnings-power value, realized if the cost program delivers its 600-million-dollar EBITDA uplift and pricing recovers. The risk is that the trough is structural rather than cyclical, in which case the normalized number itself needs to come down, and the stock would re-rate toward its asset floor instead.

Catalysts

The central catalyst is the chemical and building-products cycle turning, and the markers are pricing and volume across PVC, polyethylene, caustic soda, and the housing-products lines. Q1 2026 showed weakness in all of them, so the next quarters are a direct read on whether the trough is bottoming. Westlake's own seasonality, with stronger second and third calendar quarters on construction restocking and weather, means the mid-year prints carry extra signal about the recovery slope. Management reaffirmed a 600-million-dollar EBITDA uplift target for 2026 and a 175-million-dollar cost-savings program, so evidence those initiatives are landing, particularly in the Housing and Infrastructure segment guided to a 19-to-21-percent EBITDA margin, is the operational catalyst.

The macro catalyst is interest rates. Because the housing-products leg depends on construction demand that mortgage rates throttle, any easing in rates would directly lift the segment the company is counting on to diversify its cyclicality. The analyst and credit tape is mixed and worth tracking: JPMorgan upgraded to Neutral at a 90-dollar target citing improving free cash flow into 2027, while BofA and S&P moved more cautiously, so the debate is live. Free-cash-flow generation, projected by some analysts at roughly 3 percent of market value in 2026 rising to 8 percent in 2027, is the figure that would confirm the recovery.

Sources: Westlake Q1 2026 loss with 150M EBITDA and 2.5B cash, stocktitan.net; Westlake Corporation reports first quarter 2026 results, westlake.com; Restructuring closures and JPMorgan upgrade, simplywall.st; Westlake analyst ratings and price targets, benzinga.com.

Peer Cohorts (Per Segment, With Filing Citations)

Housing and Infrastructure Products (reported)

Performance and Essential Materials (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive WLK report on boothcheck